Subject(s)
Hyper-IgM Immunodeficiency Syndrome/diagnosis , Intestinal Polyposis/diagnosis , Peyer's Patches/pathology , Adult , B-Lymphocytes/immunology , B-Lymphocytes/metabolism , Biomarkers , Biopsy , Colonoscopy , Diagnosis, Differential , Disease Susceptibility , Germinal Center/immunology , Germinal Center/metabolism , Germinal Center/pathology , Humans , Hyper-IgM Immunodeficiency Syndrome/etiology , Immunoglobulin Class Switching/genetics , Immunoglobulin M/blood , Immunoglobulin M/genetics , Immunoglobulin M/immunology , Immunohistochemistry , Intestinal Polyposis/etiology , Male , Mutation , Symptom AssessmentABSTRACT
No disponible
Subject(s)
Humans , Male , Adult , Hyper-IgM Immunodeficiency Syndrome/immunology , Intestinal Polyps/immunology , Cytidine Deaminase/immunology , Flow Cytometry/methods , Endoscopy, Gastrointestinal/methodsABSTRACT
BACKGROUND: T-helper (Th)-17 lymphocytes and neutrophils are the main sources of the proinflammatory cytokines involved in the pathogenesis of hidradenitis suppurativa (HS). OBJECTIVES: This study aims to evaluate the improvement of the inflammatory serum markers (ISM) levels in patients with moderate-to-severe HS who receive adalimumab. METHODS: Nineteen moderate-to-severe HS patients were prospectively recruited. Each of the patients received 40â¯mg of adalimumab weekly. The ISM levels and modified Hidradenitis Suppurativa Score (mHSS) scores were assessed at baseline and at week 36. Nineteen healthy volunteers (HC) constituted the control group. RESULTS: Before adalimumab treatment, the HS patients showed significantly increased levels of interleukin (IL)-6, IL-8, IL-10, IL-17A, soluble TNF receptor II (sTNF-RII), and C-reactive protein (CRP) as well as an increased erythrocyte sedimentation rate (ESR) (all Pâ¯<â¯.01). At week 36, the circulating levels of IL-1ß, IL-6, IL-8, IL-10, IL-17A, soluble TNF receptor I (sTNF-RI), sTNF-RII, and CRP, as well as the ESR (all Pâ¯<â¯.05), decreased significantly in the HS patients who received adalimumab. The decrease in levels of IL-6 (râ¯=â¯0.65, Pâ¯=â¯.003), IL-8 (râ¯=â¯0.52, Pâ¯=â¯.024), sTNF-RI (râ¯=â¯0.55, Pâ¯=â¯.015), and CRP (râ¯=â¯0.47, Pâ¯<â¯.040) and the ESR (râ¯=â¯0.60, Pâ¯<â¯.006) were significantly well correlated with clinical improvements according to the mHSS. CONCLUSIONS: Adalimumab improves the ISM-based systemic inflammatory burden in patients with moderate-to-severe HS. IL-6, IL-8, sTNF-RI and CRP and the ESR may serve as novel biomarkers for a therapeutic response.
Subject(s)
Adalimumab/administration & dosage , Cytokines , Hidradenitis Suppurativa , Neutrophils , Th17 Cells , Adult , Cytokines/blood , Cytokines/immunology , Female , Hidradenitis Suppurativa/blood , Hidradenitis Suppurativa/drug therapy , Hidradenitis Suppurativa/immunology , Hidradenitis Suppurativa/pathology , Humans , Male , Middle Aged , Neutrophils/immunology , Neutrophils/metabolism , Neutrophils/pathology , Th17 Cells/immunology , Th17 Cells/metabolism , Th17 Cells/pathologyABSTRACT
OBJECTIVES: To assess inflammatory serum markers including serum proinflammatory cytokines, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) according to the clinical inflammatory activity of patients with hidradenitis suppurativa (HS). PATIENTS AND METHODS: Seventy-four patients with HS were studied based on the Hidradenitis Suppurativa-Physician Global Assessment (HS-PGA) score and Hurley staging system. Proinflammatory cytokines were measured using a multiplex cytokine assay. Twenty-two healthy volunteers were recruited. RESULTS: Serum interleukin- (IL-) 6, IL-23, soluble tumour necrosis factor alpha (TNF-α) receptor I (sTNF-RI), CRP, and ESR were different in the patients with HS compared with those in the healthy controls (P < 0.05). The levels of IL-1ß, IL-6, IL-8, IL-10, IL-12p70, IL-17A, sTNF-RII, CRP, and ESR were significantly elevated according to inflammatory activity based on HS-PGA scores (r > 0.25, P < 0.05). The levels of IL-6 (r = 0.53, P < 0.001), CRP (r = 0.54, P < 0.001), and ESR (r = 0.60, P < 0.001) were especially well correlated with clinical inflammatory activity based on HS-PGA scores. The levels of IL-6, IL-8, sTNF-RI, sTNF-RII, CRP, and ESR were significantly elevated according to Hurley staging system. CONCLUSIONS: Serum proinflammatory cytokines, CRP, and ESR are increased in relation to the clinical inflammatory activity of patients with HS compared with healthy controls. Serum IL-6, CRP, and ESR are effective biomarkers for evaluating the severity of HS.